In yesterday’s Wall Street session, TransCode Therapeutics Inc. (NASDAQ:RNAZ) shares traded at $0.73, down -25.50% from the previous session.
1 analysts cover TransCode Therapeutics Inc. (NASDAQ:RNAZ), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $6.00, we find $6.00. Given the previous closing price of $0.98, this indicates a potential upside of 512.24 percent. RNAZ stock price is now -8.27% away from the 50-day moving average and -53.71% away from the 200-day moving average. The market capitalization of the company currently stands at $8.83M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
The stock has received a hold rating from 0 analysts and a buy rating from 1. Brokers who have rated the stock have averaged $6.00 as their price target over the next twelve months.
.
In other news, Dudley Robert Michael, Chief Executive Officer bought 20,000 shares of the company’s stock on Sep 14. The stock was bought for $23,000 at an average price of $1.15. Upon completion of the transaction, the Chief Executive Officer now directly owns 893,114 shares in the company, valued at $0.65 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 16, Chief Financial Officer Fitzgerald Thomas A bought 12,000 shares of the business’s stock. A total of $15,240 was incurred on buying the stock at an average price of $1.27. This leaves the insider owning 139,377 shares of the company worth $0.1 million. A total of 8.00% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in RNAZ stock. In total, there are 15 active investors with 15.90% ownership of the company’s stock.
On Thursday morning TransCode Therapeutics Inc. (NASDAQ: RNAZ) stock kicked off with the opening price of $0.7160. During the past 12 months, TransCode Therapeutics Inc. has had a low of $0.37 and a high of $3.13. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.10, and a quick ratio of 3.10. The fifty day moving average price for RNAZ is $0.7960 and a two-hundred day moving average price translates $1.5773 for the stock.
The latest earnings results from TransCode Therapeutics Inc. (NASDAQ: RNAZ) was released for Jun, 2022.
TransCode Therapeutics Inc.(RNAZ) Company Profile
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company’s products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
